The Evolving Role of Cytokine Therapy for Renal Cell Carcinoma: Past, Present, and Future

Download All
Expert guidance for physicians, nurses, and pharmacists on evolving cytokine therapy for RCC.
Brendan D. Curti, MD

ClinicalThought

Despite the advance of newer immunotherapies and targeted agents for the treatment of RCC, high-dose IL-2 has an important role in achieving a durable response. Read my thoughts on when to consider it and which patients may benefit the most.

Brendan D. Curti, MD Released: August 24, 2020

Module

Explore this expert discussion of cytokine therapy in RCC, including current best practices, combinations with immunotherapy, and future directions; then download the slideset containing all the key data.

Brendan D. Curti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: October 1, 2020 Expired: No longer available for credit

Dr. Brendan Curti explores the use of cytokine therapy in the treatment of RCC, including current best practices, combinations with immunotherapy, and future directions.

Brendan D. Curti, MD Released: October 1, 2020

Clinicians Guide

Download this PDF for guidance on the safe and effective use of HD IL-2 for patients with renal cell carcinoma.

Brendan D. Curti, MD Released: November 11, 2020
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Clinigen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings